Skip to content

DIAMEDICA THERAPEUTICS INC.

DMAC

CIK 0001401040

← back to feed
Revenue (TTM)
$500K
Q1 May 2026
Net Income (TTM)
−$34.07M
−34.0% YoY Q1 May 2026
EPS Diluted (TTM)
—
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-7,133.2%
Q1 May 2026
Net Margin
-6,813.6%
Q1 May 2026
Free Cash Flow (TTM)
−$28.01M
Q1 May 2026
Cash
$4.87M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
53.88M sh
Q1 May 2026

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings